

Agenda of financial events 2013

PRINCETON, N.J. and PARIS – January 10, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing[®] stent to treat acute myocardial infarction (AMI), announced today its preliminary financial agenda for 2013.

Event	Date *
Q4 Full Year Sales 2012	24 January 2013
Full-Year Results 2012 **	28 March 2013
Q1 Sales 2013	25 April 2013
Q2 Sales 2013	25 July 2013
Half-Year Results 2013	29 August 2013
Q3 Sales 2013	24 October 2013

Financial year ended 31 December

* *Subject to modification*

** *Press release distributed before the financial markets opening*

About STENTYS:

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS's Self-Apposing[®] Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low 30-day mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. *More information is available at www.stentys.com.*

Contacts

STENTYS

Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

Europe: NewCap.

Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

US: MacDougall Biomedical Communications

Kari Watson, Tel.: +1 781 235 3060
Christine Labaree, Tel.: +1 650 339 7533
stentys@macbiocom.com

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT